The original dataset of "Evaluation of the immunogenicity of a recombinant pseudorabies virus expressing African swine fever virus p30 and CD2v proteins in mice"

African swine fever (ASF) is a highly lethal infectious disease caused by ASF virus (ASFV), affecting both domestic and wild pigs. It has imposed catastrophic economic losses on the global pig industry. Currently, no commercial vaccine with complete protective efficacy is available for the prevention and control of ASFV in China, and ASFV continues to spread across new regions. To develop a safe and effective ASFV vaccine, a recombinant pseudorabies virus (rPRV) expressing ASFV p30 and CD2v proteins (rPRV-ΔgI/gE-p30/CD2v) was constructed using CRISPR/Cas9 and homolo-gous recombination technologies. The biological properties of the recombinant virus strain were characterized, and its safety and immunogenicity were evaluated in a mu-rine model. Results demonstrated that rPRV-ΔgI/gE-p30/CD2v could stably express ASFV p30 and CD2v proteins while exhibiting significantly attenuated virulence. No systemic infection or inflammatory responses were induced in the immunized mice, confirming the good safety profile. The rPRV-ΔgI/gE-p30/CD2v successfully elicited specific anti-p30, anti-CD2v and anti-gB antibodies, activated cellular immune re-sponses, and induced a balanced Th1/Th2 immune response. In the PRV challenge experiment, rPRV-ΔgI/gE-p30/CD2v conferred 100% protection, significantly reduced viremia and viral copy numbers in tissues, and mitigated PRV-induced histopathological damage. In summary, the rPRV-ΔgI/gE-p30/CD2v ex-hibited excellent safety and robust immune protection efficacy, showing promise as a candidate strain for a dual vaccine targeting both ASFV and PRV, and offering novel strategies for the effective control of ASFV.